Table 3.
Cancer-specific survival according to CDX2 and SATB2 expression in Cohort 1 and 2
| Cohort 1 | Cohort 2 | |||||||
|---|---|---|---|---|---|---|---|---|
| No. of cases | No. of events | Univariable HR (95% CI) | Multivariable HR (95% CI) | No. of cases | No. of events | Univariable HR (95% CI) | Multivariable HR (95% CI) | |
| CDX2 | ||||||||
| High | 1168 | 305 | 1 (referent) | 1 (referent) | 896 | 171 | 1 (referent) | 1 (referent) |
| Low | 91 | 33 | 1.68 (1.18–2.41) | 1.88 (1.23–2.81) | 50 | 14 | 1.51 (0.87–2.60) | 1.25 (0.67–2.32) |
| Negative | 30 | 16 | 2.90 (1.75–4.80) | 3.62 (2.08–6.31) | 22 | 11 | 3.86 (2.10–7.10) | 3.55 (1.72–7.31) |
| ptrend | <0.0001 | <0.0001 | <0.0001 | 0.003 | ||||
| SATB2 | ||||||||
| High | 981 | 241 | 1 (referent) | 1 (referent) | 645 | 108 | 1 (referent) | 1 (referent) |
| Low | 255 | 95 | 1.82 (1.44–2.31) | 1.47 (1.15–1.89) | 204 | 52 | 1.45 (1.04–2.02) | 1.32 (0.93–1.89) |
| Negative | 53 | 18 | 1.72 (1.07–2.78) | 1.61 (0.97–2.67) | 119 | 36 | 1.86 (1.28–2.72) | 1.75 (1.15–2.67) |
| ptrend | <0.0001 | 0.002 | 0.0005 | 0.007 | ||||
Multivariable Cox proportional hazards regression models were adjusted for sex, age (< 65, 65–75, and > 75), year of operation (Cohort 1: 2000–2005, 2006–2010, and 2011–2015, Cohort 2: 2006–2010, 2011–2015, and 2016–2020), tumor location (proximal colon, distal colon, and rectum), disease stage (I, II, III, and IV), tumor grade (well/moderately differentiated and poorly differentiated), lymphovascular invasion (negative and positive), MMR status (proficient and deficient), BRAF status (wild-type and mutant), and preoperative radiotherapy or chemoradiotherapy (no and yes)
ptrend values were calculated by using the three ordinal categories of CDX2 histoscore and SATB2 histoscore as continuous variables in univariable and multivariable Cox proportional hazard regression models
CI confidence interval and HR hazard ratio